AI Article Synopsis
- This study analyzed adverse events (AEs) related to brolucizumab using the FDA Adverse Event Reporting System (FAERS) database from October 2019 to March 2023.
- A total of 3,313 AEs were specifically linked to brolucizumab, revealing 150 ocular AE signals, with many being known issues and some unexpected.
- Additionally, systemic AEs like arterial thromboembolic events were noted, indicating potential safety concerns with brolucizumab in real-world settings.
Article Abstract
Background: The safety information of brolucizumab primarily comes from clinical trials experience. This study aimed to explore the ocular and systemic adverse events (AEs) associated with brolucizumab among real-world patients through data mining the FDA Adverse Event Reporting System (FAERS) database.
Methods: AE reports submitted to the FAERS database between October 2019 and March 2023 were extracted. The reporting odds ratio was used to evaluate AE signals associated with brolucizumab.
Results: There were 4,380,839 AE reports extracted from the FAERS database, and 3,313 of which were with brolucizumab as primary suspected. A total of 150 ocular AE signals were identified. Ninety-nine were known ocular AEs listed in brolucizumab' label, primarily including vision-related AEs, intraocular infections, and retinal disorders. Fifty-one were unexpected ocular AE signals, including keratic precipitates, retinal perivascular sheathing, dry eye, glaucoma, etc. Meanwhile, several serious systemic AE signals, including arterial thromboembolic events and rhinorrhea, were also identified.
Conclusions: Several unexpected ocular and systemic AE signals associated with brolucizumab were identified through data mining of the FAERS database.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2024.2322712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraocular Inflammation Following Intravitreal Faricimab Injection in Neovascular Age-Related Macular Degeneration.
Cureus
December 2024
Ophthalmology, Drishti Eye Institute, Dehradun, IND.
We herein report intraocular inflammation (IOI) following intravitreal (IVT) faricimab injection in three patients. A 73-year-old male, a 68-year-old female, and an 82-year-old female, all diagnosed with neovascular age-related macular degeneration (AMD), had received multiple anti-vascular endothelial growth factor (anti-VEGF) injections for the same. They were injected with IVT faricimab due to non-response to other agents.
View Article and Find Full Text PDFThe Safety of Recently Approved Therapeutics in Age-Related Macular Degeneration.
Int Ophthalmol Clin
January 2025
University of Nevada, Reno School of Medicine, Reno, NV.
Recent developments in treatments for both forms of advanced age-related macular degeneration (AMD) have led to the approval of multiple agents and modalities within the last few years. Five new medications for both neovascular AMD (nAMD) and geographic atrophy (GA) secondary to nonexudative AMD (neAMD) have been FDA-approved within the last 5 years, along with a new device designed for sustained drug delivery for nAMD. In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F.
View Article and Find Full Text PDFAssociation of metabolomic aging acceleration and body mass index phenotypes with mortality and obesity-related morbidities.
Aging Cell
December 2024
Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
This study aims to investigate the association between metabolomic aging acceleration and body mass index (BMI) phenotypes with mortality and obesity-related morbidities (ORMs). 85,458 participants were included from the UK Biobank. Metabolomic age was determined using 168 metabolites.
View Article and Find Full Text PDFEffects on corneal endothelium of intravitreal injection of anti-VEGF drugs.
Cutan Ocul Toxicol
December 2024
Department of Sense Organs, Sapienza University of Rome, Rome, Italy.
Article Synopsis
- * Researchers analyzed a group of 133 patients with retinal diseases like age-related macular degeneration (AMD), collecting data on corneal endothelial cell counts before and after multiple injections of different anti-VEGF medications.
- * The primary goal was to establish a link between these injections and any significant decrease in endothelial cell counts in the treated eyes compared to untreated ones, while also comparing the toxicity levels between various anti-VEGF drugs used in the treatments.
Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database.
Clin Exp Ophthalmol
October 2024
Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Background: This study aims to assess the risk of drug-associated glaucoma and track its epidemiological characteristics using real-world data.
Methods: Adverse event reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to December 2023 were analysed. Disproportionality analysis and the Bayesian Confidence Propagation Neural Network algorithm were used.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!